Product Description
Qnexa (VI-0521) is an investigational fixed-dose combination drug of phentermine and topiramate currently in Phase III clinical trials for the treatment of obesity.Ê (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369742/)
Mechanisms of Action: ADR Agonist, GABA Binder
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: VIVUS
Company Location: CAMPBELL CA 95008
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Pediatric Obesity|Overweight|Obesity
Phase 3: Obesity|Type 2 Diabetes
Phase 2: Overweight|Obesity|Sleep Apnea, Obstructive|Type 2 Diabetes|Glucose Metabolism Disorders
Phase 1: Obesity|Torsades de Pointes|Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00839891 |
TQT | P1 |
Completed |
Torsades de Pointes |
2009-04-01 |
2021-12-09 |
Primary Endpoints|Treatments |
|
NCT00821496 |
OB-108 | P1 |
Completed |
Healthy Volunteers |
2009-03-01 |
2021-12-09 |
Primary Endpoints|Treatments |
|
NCT00842400 |
OB-107 | P1 |
Completed |
Obesity |
2009-03-01 |
2021-12-09 |
Primary Endpoints|Treatments |
|
NCT00745251 |
OB-204 | P2 |
Completed |
Sleep Apnea, Obstructive |
2009-09-01 |
2021-12-09 |
Primary Endpoints|Treatments |
|
NCT00806260 |
OB-205 | P2 |
Completed |
Overweight|Obesity |
2009-05-01 |
2021-12-09 |
Primary Endpoints|Treatments |
|
NCT00737633 |
DM-231 | P2 |
Terminated |
Glucose Metabolism Disorders|Type 2 Diabetes |
2009-03-01 |
2021-12-09 |
Primary Endpoints|Treatments |
|
NCT00486291 |
OB-202 | P2 |
Completed |
Type 2 Diabetes |
2008-04-01 |
2021-12-09 |
Primary Endpoints|Treatments |
|
NCT00796367 |
NCT00553787 | P3 |
Completed |
Obesity |
2010-06-01 |
2021-12-09 |
Primary Endpoints|Treatments |
|
NCT00553787 |
OB-303 | P3 |
Completed |
Type 2 Diabetes|Obesity |
2009-06-01 |
2021-12-09 |
Primary Endpoints|Treatments |
|
NCT00554216 |
OB-302 | P3 |
Completed |
Obesity |
2009-05-01 |
2021-12-09 |
Primary Endpoints|Treatments |
|
NCT00563368 |
OB-301 | P3 |
Completed |
Obesity |
2008-09-01 |
2021-12-09 |
Primary Endpoints|Treatments |
|
NCT05215418 |
OB-409 | P4 |
Completed |
Overweight |
2023-04-11 |
2024-06-28 |
Patient Enrollment|Primary Endpoints|Treatments |
|
NCT03922945 |
OB-403 | P4 |
Completed |
Pediatric Obesity|Overweight |
2021-04-16 |
2022-03-04 |
Primary Endpoints|Treatments |
|
NCT02714062 |
OB-402 | P4 |
Completed |
Pediatric Obesity |
2016-10-01 |
2021-12-09 |
Primary Endpoints|Treatments |
|
NCT02229214 |
OB-404 | P4 |
Completed |
Overweight|Obesity |
2014-11-01 |
2021-12-09 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|